Novel Treatments & Drugs

Legitimate Data and Research is Required for Treatment Approval

For cancer patients who have little success with traditional chemotherapy and radiation treatments, immunotherapy treatments are becoming known alternatives – working with the body’s own immune system to become stronger and better able to fight cancer cells and other infections. A mesothelioma diagnosis is often grim, with survival rates at[…]

Read More »

Autophagy Inhibitors Potentially Make Chemotherapy More Effective in Mesothelioma Patients

Autophagy is a natural and regulated self-degradative process in cells that plays a critical role in balancing sources of energy and removing aggravated proteins, damaged organelles, and pathogens. During autophagy, cells break down and recycle their different parts in order to make new cells. In mesothelioma, autophagy is necessary for[…]

Read More »

Bevacizumab – A Positive Treatment with Serious Side Effects

Bevacizumab (Avastin) is commonly viewed as chemotherapy treatment because when administered intravenously, it is particularly effective in controlling such illnesses such as lung cancer and colon cancer. However, it is a bit different than traditional chemotherapy treatments, which directly attack cancer cells. Bevacizumab fights cancer cells by cutting off oxygen[…]

Read More »

Opdivo, Yervoy, and Keytruda: Immunotherapy Options for Mesothelioma

Immunotherapy treatments are becoming known alternatives to chemotherapy in cancer patients who have had little success with traditional cancer treatments. With mesothelioma, often times first line treatments have little effect because the cancer is typically in the advanced stages by the time it is detected.  While there currently is no[…]

Read More »

Determining and Prolonging Survival Rates In Mesothelioma

The average survival rate for mesothelioma after diagnosis is less than one year; however, certain individuals will survive longer than others, but the reason as to why this is, is largely unknown.  The latest study to be published in Histopathology investigates what it is in the body that determines a[…]

Read More »

Trimodality Therapy Increases Survival; Immunotherapy Treatment Approved by FDA

Since mesothelioma is often difficult to treat, scientists and researchers look to combination treatments and therapies to improve chances of patients’ survival. There is no “one” treatment that is used across the board in treating mesothelioma, because patients react differently, whether it is to chemotherapy, radiation therapy, immunotherapy, or surgery.[…]

Read More »

Two Potential Mesothelioma Treatments Have No Positive Effect

Tremelimumab Earlier in the spring of 2017, scientists and researchers from the University of Salford in the UK published a special report questioning the effectiveness of the new immunotherapy treatment known as tremelimumab. Trials of the check point inhibitor did not show promising results and there was concern about the[…]

Read More »

Improvements in Radiation Therapies Give More Treatment Options

When it comes to different treatments for mesothelioma patients, there is no shortage of diversity, as options include chemotherapy, radiation, surgery, immune-based therapies, gene-based therapies, and more. Chemotherapy treatments cisplatin and pemetrexed are first line treatments, especially among those who do not quality for surgery. Radiation treatment is available, but[…]

Read More »

Mesothelioma Patients Receive Zoledronic Acid as Treatment

Known as a bisphosphonate, zoledronic acid is typically used for bone diseases such as osteoporosis, and to treat high calcium levels in the blood that can lead to other health complications.  Nitrogen containing bisphosphonates like zoledronic acid are known to have cancer suppressing qualities, and scientists and researchers were eager[…]

Read More »

Giving Cediranib Another Chance

A Phase I study for cediranib, a VEGFR/PDGFR kinase inhibitor, showed promising results in shrinking tumor size and increasing survival rates for those suffering from malignant pleural mesothelioma. This is not the first time cediranib has been studied as a possible treatment for mesothelioma. In 2011/2012 a Phase II trial[…]

Read More »